Updated
November 6th, 2019

HIV Vaccine Candidate Launched Phase 1 Study

GeoVax Labs will provide its novel MVA-VLP HIV vaccine (MVA62B) in combination with AGT103-T in a clinical trial

man taking a photo with camera

Georgia based GeoVax Labs said it will participate in a planned clinical trial to develop a therapy aimed at eliminating HIV from infected people.

Previously, American Gene Technologies (AGT) announced on October 18, 2019, the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, a lentiviral vector-based gene therapy.

This is important news since the average lifetime medical costs of treating an HIV-positive individual in the USA is about $350,000.

Pursuant to its collaboration agreement with AGT, GeoVax will provide its novel MVA-VLP HIV vaccine (MVA62B) for evaluation in an arm of the clinical trial in combination with AGT103-T.

MVA62B is the boosting component for GeoVax’s preventive HIV vaccine (GOVX-B11) which has successfully completed a Phase 2a clinical trial and is awaiting funding in support of a Phase 2b pivotal clinical trial.

Upon clearance by the FDA, this IND will allow AGT to initiate a Phase 1 clinical trial that will investigate the safety of AGT103-T in humans, measure key biomarkers, and explore surrogate markers of efficacy.

T cells obtained from vaccinated individuals will be reprogrammed by AGT’s lentivirus vector and infused back into the study participants as a therapeutic cell product. 

Sponsored Links:

AGT expects to begin recruiting patients for the Phase 1 study in January.

Farshad Guirakhoo, Ph.D., GeoVax’s Chief Scientific Officer, commented in a press release, “In a previous therapeutic Phase 1 clinical trial conducted by GeoVax, we demonstrated that our vaccine can potently stimulate production of both CD8+ and CD4+ T cells in HIV-positive individuals – the intended use of the MVA62B vaccine in the proposed AGT therapeutic study.”

“Our vaccine also has a well-documented safety profile in >500 humans. We are hopeful that the combination of technologies in these studies will yield a promising regimen that eliminates the HIV reservoir from people infected with the disease in the absence of antiretroviral drugs.”

David Dodd, GeoVax’s President and CEO, stated, “While current antiretroviral therapy is effective at suppressing the viral load of HIV-infected individuals and preventing progression to AIDS, the long-term use of ART can lead to loss of drug effectiveness and can come with severe side effects.”

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.

For more information, visit GeoVax.